(Q38579008)

English

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).

scientific article published on 02 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). (English)

1 reference

Europe PubMed Central

4 September 2017

0 references

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Barbara Eichhorst

3

object named as

Barbara Eichhorst

0 references

4

object named as

Michael Hallek

1 reference

Europe PubMed Central

4 September 2017

author name string

Paula Cramer

1

1 reference

Europe PubMed Central

4 September 2017

Petra Langerbeins

2

1 reference

Europe PubMed Central

4 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 September 2015

1 reference

Europe PubMed Central

4 September 2017

European Journal of Haematology

1 reference

Europe PubMed Central

4 September 2017

96

1 reference

Europe PubMed Central

4 September 2017

1

1 reference

Europe PubMed Central

4 September 2017

9-18

1 reference

Europe PubMed Central

4 September 2017

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Disease burden of chronic lymphocytic leukaemia within the European Union

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Sex differences in incidence and outcome of chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Karyotypic evolution in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Treatment of elderly patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Cumulative illness rating scale

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Targeting the B cell receptor pathway in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12678

21 January 2018

Identifiers

10.1111/EJH.12678

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38579008&oldid=1634910728"